Compare NNI & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNI | BLTE |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.1B |
| IPO Year | 2003 | 2022 |
| Metric | NNI | BLTE |
|---|---|---|
| Price | $128.76 | $149.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $135.00 | ★ $149.00 |
| AVG Volume (30 Days) | 119.6K | ★ 246.7K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 288.59 | N/A |
| EPS | ★ 11.91 | N/A |
| Revenue | ★ $1,698,851,000.00 | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $6.27 | N/A |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | ★ 35.52 | N/A |
| 52 Week Low | $98.15 | $49.00 |
| 52 Week High | $136.68 | $160.55 |
| Indicator | NNI | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 69.65 |
| Support Level | $129.36 | $140.07 |
| Resistance Level | $134.39 | $160.55 |
| Average True Range (ATR) | 3.20 | 12.76 |
| MACD | 0.23 | 1.29 |
| Stochastic Oscillator | 57.05 | 80.13 |
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.